MitoQ for vitiligo by mitigating PARP1 translocation aberrations: Network pharmacology and experimental validation

Area of Science:

• Dermatology and Molecular Medicine
• Investigating the molecular mechanisms of skin diseases
• Exploring novel therapeutic targets for autoimmune disorders

Background:

• Oxidative stress is a key factor in vitiligo pathogenesis.
• Mitoquinone (MitoQ), a mitochondria-targeted antioxidant, shows therapeutic potential in various diseases.
• The precise role of MitoQ in vitiligo treatment requires elucidation.

Purpose of the Study:

• To investigate the potential molecular targets of MitoQ in vitiligo.
• To explore the therapeutic mechanisms of MitoQ in vitiligo.
• To identify novel therapeutic strategies for vitiligo.

Main Methods:

• Network pharmacology and molecular docking to identify MitoQ targets.
• Transcriptomic analysis to assess gene expression changes.
• In vitro experiments to validate MitoQ's effects on oxidative stress and cellular senescence.

Main Results:

• Identified poly (ADP-ribose) polymerase 1 (PARP1) as a crucial target of MitoQ in vitiligo.
• MitoQ alleviated oxidative stress, restored mitochondrial function, and reduced DNA damage-related gene expression.
• MitoQ decreased cellular senescence by downregulating CDKN1A/p21 via PARP1, and PARP1 knockdown reduced oxidative damage.

Conclusions:

• PARP1 plays a significant role in mitigating cellular senescence in vitiligo.
• Targeting PARP1 with MitoQ presents a promising therapeutic avenue for vitiligo.
• Further research into PARP1-mediated mechanisms could lead to effective vitiligo treatments.